AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP) Initial study will enable further collaboration on the predictive capabilities of StemPrintER GlobeNewswire January 08, 2026 PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with […]

Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study GlobeNewswire January 08, 2026 Combination of AT7687 and cagrilintide demonstrated enhanced weight loss effect in obese, insulin-resistant, pre-diabetic non-human primate (NHP) model Additional weight loss observed in combination group

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 million GlobeNewswire January 08, 2026 BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today

CMR Surgical receives CE Mark for use of Versius in paediatric surgery GlobeNewswire January 08, 2026 CMR Surgical receives CE Mark for use of Versius in paediatric surgery Small, modular design of the Versius system supports use in robotic-assisted paediatric surgery Cambridge, UK – 8 January 2026, CMR Surgical ('CMR' or 'the Company'), the global

Indivior Provides Full-Year 2026 Financial Guidance and Business Update GlobeNewswire January 08, 2026 Total Net Revenue Expected in the Range of $1,125 million to $1,195 million Total SUBLOCADE(R) Net Revenue Expected to be in the Range of $905 million to $945 million Non-GAAP Operating Expenses Expected in the Range of $430 million to $450 million

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases GlobeNewswire January 08, 2026 — Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – — Expects to initiate global Phase 1/2 MAD

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy GlobeNewswire January 08, 2026 Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies, including Impella(TM) heart pumps Agreement will enable accelerated development of a preclinical cardiac target using novel, localized

AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 08, 2026 LONDON and MILAN, Jan. 08, 2026 (GLOBE NEWSWIRE) — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January

Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS Company Expects to Report Topline Data in Q4 2026 GlobeNewswire January 08, 2026 CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is

(TSX:FURY),(NYSE MKT:FURY), TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX: FURY, NYSE American: FURY) (“Fury” or the “Company“) is pleased to provide a review of 2025 corporate and technical achievements, including exploration drilling across four gold properties (Eleonore South, Sakami, Committee Bay and Eau Claire), meaningful portfolio expansion in Quebec via